Medical Pharmacology: Chapter 33 — Anti-Cancer Drugs Part I -- Module 2

Chapter 33 — Anti-Cancer Drugs Part I — Module 2 — Alkylating Agents

1. [CASE 1 — QUESTION 1] A 24-year-old man presents with a metastatic nonseminomatous germ cell tumor of the testis (a highly chemosensitive, potentially curable malignancy). His performance status is excellent, baseline serum creatinine is 0.9 mg/dL with a normal estimated GFR (glomerular filtration rate), audiometry is normal, and the oncology team plans curative-intent BEP (bleomycin, etoposide, platinum). A trainee asks whether carboplatin could replace cisplatin to spare nephrotoxicity. Which choice of platinum agent is correct, and why?

A) Carboplatin, because it produces identical platinum-DNA adducts and is therefore interchangeable with cisplatin in every regimen
B) Carboplatin, because in any curative-intent setting the lower toxicity profile outweighs efficacy considerations
C) Cisplatin, because the curative outcome data in testicular germ cell tumors are specific to cisplatin and carboplatin underperforms in this setting
D) Oxaliplatin, because its DACH carrier ligand makes it the most potent platinum for germ cell tumors
E) No platinum agent, because germ cell tumors are intrinsically platinum-resistant at first presentation

ANSWER: C

Rationale:

Option C is correct. Although cisplatin and carboplatin share the platinum-DNA adduct mechanism, the curative outcome data in testicular germ cell tumors are specific to cisplatin, and carboplatin underperforms in this curative-intent setting. With normal renal function and audiometry, cisplatin can be given safely with aggressive hydration, and preserving cure probability takes priority over the milder toxicity profile of carboplatin.

Option A: Option A is incorrect because identical adduct chemistry does not make the agents interchangeable in curative regimens where the outcome data are cisplatin-specific.
Option B: Option B is incorrect because in a curable disease the overriding goal is maintaining cure probability, so lower toxicity does not justify substitution here.
Option D: Option D is incorrect because oxaliplatin is used in colorectal and selected gastrointestinal cancers, not germ cell tumors, and is not the standard platinum here.
Option E: Option E is incorrect because germ cell tumors are highly platinum-sensitive at presentation; platinum-based therapy is the foundation of cure.

2. [CASE 1 — QUESTION 2] Continuing with the same patient, the team prepares to administer the first cisplatin dose and reviews the supportive-care order set. Which approach best reflects appropriate cisplatin nephroprotection?

A) Pre- and post-infusion normal saline hydration with magnesium supplementation, and avoidance of concurrent nephrotoxic agents
B) Fluid restriction to concentrate the drug at the tumor, with no electrolyte supplementation
C) Routine mesna administration to prevent cisplatin-induced hemorrhagic cystitis
D) Empiric methylene blue before each dose to prevent cisplatin neurotoxicity
E) Alkaline diuresis with intravenous bicarbonate as the sole protective measure, omitting saline

ANSWER: A

Rationale:

Option A is correct. Cisplatin nephrotoxicity is prevented by meticulous pre- and post-infusion hydration with normal saline, magnesium supplementation in every cycle (renal magnesium wasting is common and often dose-limiting), and avoidance of concurrent nephrotoxins. This bundle directly counters the proximal tubular injury that defines cisplatin renal toxicity.

Option B: Option B is incorrect because fluid restriction worsens cisplatin nephrotoxicity; aggressive saline hydration is required, along with electrolyte repletion.
Option C: Option C is incorrect because mesna prevents acrolein-mediated hemorrhagic cystitis from cyclophosphamide and ifosfamide, not cisplatin nephrotoxicity.
Option D: Option D is incorrect because methylene blue treats ifosfamide encephalopathy and has no role in cisplatin nephroprotection.
Option E: Option E is incorrect because saline hydration is the cornerstone of cisplatin nephroprotection; bicarbonate alone without saline does not provide adequate protection.

3. [CASE 1 — QUESTION 3] Continuing with the same patient, during cycle 2 he develops febrile neutropenia, and the covering team considers adding an aminoglycoside antibiotic for empiric gram-negative coverage. Considering his recent cisplatin exposure, what is the most appropriate concern and action?

A) Aminoglycosides have no interaction with cisplatin and may be added without additional monitoring
B) Aminoglycosides compound cisplatin nephrotoxicity and ototoxicity, so a non-nephrotoxic alternative should be preferred if clinically adequate, with close renal and otologic monitoring if an aminoglycoside is unavoidable
C) Aminoglycosides protect the kidney from platinum injury and should be added routinely after cisplatin
D) Aminoglycosides should be avoided only because they cause hemorrhagic cystitis when combined with cisplatin
E) Aminoglycosides reverse cisplatin-induced hypomagnesemia and are therefore beneficial in this setting

ANSWER: B

Rationale:

Option B is correct. Aminoglycosides are independently nephrotoxic and ototoxic, and given concurrently with cisplatin they compound both toxicities, reducing GFR and worsening the cumulative renal and otologic injury. The appropriate approach is to prefer a non-nephrotoxic antibiotic when one provides adequate coverage, and if an aminoglycoside is truly necessary, to use it with close renal function and audiometric monitoring.

Option A: Option A is incorrect because the combination clearly compounds nephrotoxicity and ototoxicity and demands caution and monitoring.
Option C: Option C is incorrect because aminoglycosides injure rather than protect the kidney.
Option D: Option D is incorrect because the concern is additive nephrotoxicity and ototoxicity, not hemorrhagic cystitis, which is an acrolein-related toxicity of cyclophosphamide and ifosfamide.
Option E: Option E is incorrect because aminoglycosides do not correct hypomagnesemia; they add to renal injury that can worsen electrolyte wasting.

4. [CASE 1 — QUESTION 4] Continuing with the same patient, he initially achieves remission but relapses two years later with disease that progresses on repeat platinum-based therapy. Molecular profiling of the relapsed tumor reports high ERCC1 (excision repair cross-complementation group 1) expression. How should this finding be interpreted?

A) High ERCC1 predicts increased platinum sensitivity, supporting escalation of the cisplatin dose
B) ERCC1 is a platinum-uptake transporter, so high expression means excessive intracellular drug and mandates dose reduction
C) High ERCC1 indicates silenced MGMT, predicting benefit from adding temozolomide
D) High ERCC1 reflects efficient nucleotide excision repair of platinum adducts and correlates with platinum resistance, supporting a shift away from further platinum-based therapy
E) ERCC1 expression is irrelevant to platinum outcomes and should not influence subsequent decisions

ANSWER: D

Rationale:

Option D is correct. ERCC1, as the key incision endonuclease of nucleotide excision repair (NER), removes platinum-DNA adducts. High ERCC1 expression signals efficient adduct repair and correlates with platinum resistance, consistent with this patient's progression on repeat platinum therapy and supporting a move toward non-platinum-based options.

Option A: Option A is incorrect because high ERCC1 predicts resistance, not enhanced sensitivity; escalating cisplatin is not the answer.
Option B: Option B is incorrect because ERCC1 is a repair endonuclease, not an uptake transporter; the issue is adduct repair, not drug accumulation.
Option C: Option C is incorrect because ERCC1 is unrelated to MGMT status; MGMT promoter methylation, not ERCC1, predicts temozolomide benefit.
Option E: Option E is incorrect because ERCC1 is a recognized predictive marker that correlates inversely with platinum sensitivity and is relevant to planning.

5. [CASE 2 — QUESTION 1] A 59-year-old woman with newly diagnosed glioblastoma multiforme (GBM, an aggressive primary brain tumor) undergoes maximal safe resection. Tumor testing reports a methylated MGMT (O6-methylguanine-DNA methyltransferase) promoter. The neuro-oncology team plans the Stupp protocol (concurrent daily temozolomide with radiation, followed by adjuvant temozolomide). How should the MGMT result be interpreted with respect to temozolomide benefit, and why?

A) It predicts reduced temozolomide benefit, because methylation increases MGMT expression and accelerates repair of O6-guanine lesions
B) It predicts favorable temozolomide benefit, because promoter methylation silences MGMT so that O6-methylguanine lesions persist and drive tumor cell death
C) It is irrelevant to temozolomide and informs only the choice between nitrosoureas
D) It predicts increased temozolomide nephrotoxicity, requiring saline hydration with each dose
E) It predicts the need for intrathecal temozolomide to overcome the repair enzyme

ANSWER: B

Rationale:

Option B is correct. A methylated MGMT promoter silences the repair enzyme, so temozolomide-induced O6-methylguanine lesions are not reversed; the persistent lesions generate futile mismatch repair, double-strand breaks, and apoptosis. Methylated tumors are therefore more than twice as likely to respond, making this a favorable predictive finding for temozolomide benefit.

Option A: Option A is incorrect because promoter methylation silences rather than increases MGMT expression; high (unmethylated) expression is what accelerates repair and predicts reduced benefit.
Option C: Option C is incorrect because MGMT methylation is the strongest predictor of temozolomide benefit and is highly relevant to temozolomide, not merely to nitrosourea selection.
Option D: Option D is incorrect because temozolomide's dose-limiting toxicity is myelosuppression, not nephrotoxicity, and methylation does not predict renal injury.
Option E: Option E is incorrect because temozolomide is given orally with good central nervous system penetration; intrathecal administration is not used and does not overcome MGMT.

6. [CASE 2 — QUESTION 2] Continuing with the same patient, she begins concurrent daily temozolomide with radiation. Which supportive measure is specifically indicated during this concurrent chemoradiation phase?

A) Routine mesna administration to prevent temozolomide-induced hemorrhagic cystitis
B) Mandatory saline hydration with magnesium repletion before each temozolomide dose
C) Prophylactic anticoagulation, because temozolomide is strongly thrombogenic
D) Empiric methylene blue to prevent temozolomide-associated encephalopathy
E) Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim-sulfamethoxazole, because of sustained lymphodepletion

ANSWER: E

Rationale:

Option E is correct. Concurrent temozolomide with radiation produces sustained lymphopenia, creating a meaningful risk of Pneumocystis jirovecii pneumonia. Prophylaxis with trimethoprim-sulfamethoxazole is therefore indicated during the concurrent chemoradiation phase and is commonly continued during adjuvant therapy given the prolonged lymphodepletion.

Option A: Option A is incorrect because temozolomide does not cause acrolein-mediated hemorrhagic cystitis; mesna is used with cyclophosphamide and ifosfamide.
Option B: Option B is incorrect because temozolomide is not nephrotoxic in the manner of cisplatin, so mandatory saline-and-magnesium hydration is not the indicated measure.
Option C: Option C is incorrect because routine prophylactic anticoagulation is not a standard temozolomide supportive measure; the specific need here is Pneumocystis prophylaxis.
Option D: Option D is incorrect because methylene blue treats ifosfamide encephalopathy, not a temozolomide complication.

7. [CASE 2 — QUESTION 3] Continuing with the same patient, at week 5 of concurrent therapy her complete blood count shows a platelet count of 70,000/microliter and marked lymphopenia. What is the most appropriate interpretation and response?

A) This is an expected nutritional anemia; continue temozolomide unchanged and supplement iron
B) This is hemorrhagic cystitis-related blood loss; administer mesna and transfuse platelets
C) This is temozolomide-induced myelosuppression, the dose-limiting toxicity; monitor counts closely, hold or adjust dosing per protocol, and continue Pneumocystis prophylaxis
D) This reflects sinusoidal obstruction syndrome; begin defibrotide and restrict fluids
E) This is cisplatin-type marrow suppression; switch to carboplatin to reduce thrombocytopenia

ANSWER: C

Rationale:

Option C is correct. Myelosuppression, predominantly thrombocytopenia and lymphopenia, is the dose-limiting toxicity of temozolomide. The appropriate response is close hematologic monitoring with holding or dose adjustment per protocol thresholds, transfusion support if clinically indicated, and continued Pneumocystis prophylaxis given the lymphodepletion.

Option A: Option A is incorrect because thrombocytopenia with lymphopenia is drug-induced myelosuppression, not nutritional anemia.
Option B: Option B is incorrect because temozolomide does not cause hemorrhagic cystitis, and mesna is not relevant; the cytopenias reflect marrow suppression.
Option D: Option D is incorrect because sinusoidal obstruction syndrome is a hepatic complication of high-dose busulfan conditioning, not a temozolomide cytopenia.
Option E: Option E is incorrect because the patient is receiving temozolomide, not cisplatin, and switching to carboplatin is not the management of temozolomide myelosuppression.

8. [CASE 2 — QUESTION 4] Continuing with the same patient, a colleague proposes substituting a nitrosourea (lomustine) for temozolomide and assumes the methylated MGMT promoter will predict nitrosourea benefit in the same binary way it predicts temozolomide benefit. He also asks how temozolomide is activated. Which statement is most accurate?

A) MGMT methylation does not predict nitrosourea response in the same binary fashion as temozolomide, because nitrosourea DNA lesions are processed differently; temozolomide is activated by spontaneous non-enzymatic hydrolysis to MTIC
B) MGMT methylation predicts nitrosourea response identically to temozolomide, and temozolomide requires hepatic CYP activation
C) MGMT methylation is irrelevant to both drugs, and temozolomide is activated by monoamine oxidase
D) MGMT methylation predicts nitrosourea response but not temozolomide response, and temozolomide is activated by renal enzymes
E) MGMT methylation predicts response only to platinum agents, and temozolomide is a direct-acting alkylator requiring no activation

ANSWER: A

Rationale:

Option A is correct. MGMT promoter methylation is the strongest predictor of temozolomide benefit, but it does not predict nitrosourea (lomustine, carmustine) response in the same binary fashion, because nitrosourea DNA lesions are processed differently from the O6-methylguanine lesion central to temozolomide cytotoxicity. Temozolomide itself is activated by spontaneous, non-enzymatic hydrolysis at physiological pH to MTIC, which is why it is orally effective and CNS (central nervous system)-penetrant.

Option B: Option B is incorrect because MGMT does not predict nitrosourea response identically, and temozolomide is not activated by hepatic CYP metabolism.
Option C: Option C is incorrect because MGMT methylation is highly relevant to temozolomide, and temozolomide is not activated by monoamine oxidase, which is relevant to procarbazine instead.
Option D: Option D is incorrect because MGMT methylation predicts temozolomide benefit, and temozolomide is activated by spontaneous hydrolysis, not renal enzymes.
Option E: Option E is incorrect because MGMT methylation predicts temozolomide benefit rather than platinum response, and temozolomide is a prodrug requiring spontaneous hydrolysis to MTIC, not a direct-acting agent.

9. [CASE 3 — QUESTION 1] A 52-year-old woman receiving high-dose cyclophosphamide as part of a stem cell mobilization regimen for breast cancer develops dysuria and gross hematuria on the second day of treatment. Urinalysis confirms hematuria without casts and a negative culture. What is the most appropriate next step?

A) Discontinue cyclophosphamide permanently and substitute a platinum agent for the remainder of therapy
B) Begin broad-spectrum antibiotics for presumed hemorrhagic urinary tract infection
C) Administer intravenous methylene blue to reverse the urotoxic metabolite
D) Continue cyclophosphamide unchanged and observe, since hematuria is expected and self-limited
E) Begin aggressive intravenous hydration and administer mesna to bind urinary acrolein

ANSWER: E

Rationale:

Option E is correct. The presentation is cyclophosphamide-induced hemorrhagic cystitis, caused by acrolein concentrated in the bladder lumen. Management combines aggressive hydration to dilute and flush urinary acrolein with mesna, whose thiol group binds acrolein to form a non-toxic conjugate, directly targeting the responsible metabolite.

Option A: Option A is incorrect because hemorrhagic cystitis is managed with hydration and mesna rather than mandating permanent discontinuation and a platinum switch as the immediate step.
Option B: Option B is incorrect because the urinalysis and negative culture show no infection; antibiotics do not address acrolein-mediated urothelial injury.
Option C: Option C is incorrect because methylene blue treats ifosfamide encephalopathy, not hemorrhagic cystitis, and does not bind acrolein.
Option D: Option D is incorrect because gross hematuria from hemorrhagic cystitis is not benign and requires hydration and mesna, not observation alone.

10. [CASE 3 — QUESTION 2] Continuing with the same patient, she is also receiving prophylactic voriconazole, a potent CYP3A4 (cytochrome P450 3A4) inhibitor, during her conditioning. Integrating cyclophosphamide's activation with this interaction, what is the most likely consequence?

A) Increased acrolein generation and worse hemorrhagic cystitis from accelerated prodrug turnover
B) Enhanced antitumor effect from induction of cyclophosphamide-activating enzymes
C) Reduced conversion of cyclophosphamide to its active alkylating metabolite, potentially compromising antitumor efficacy
D) No interaction, because cyclophosphamide is activated by spontaneous hydrolysis independent of enzymes
E) Reduced renal clearance of active metabolites, sharply increasing systemic toxicity

ANSWER: C

Rationale:

Option C is correct. Cyclophosphamide is a prodrug activated by cytochrome P450 enzymes, principally CYP2B6 with a contribution from CYP3A4. Voriconazole is a potent CYP3A4 inhibitor, so co-administration reduces conversion of cyclophosphamide to its active alkylating metabolite, potentially compromising antitumor effect. This is clinically relevant because hematology patients frequently receive prophylactic azoles during conditioning.

Option A: Option A is incorrect because CYP inhibition reduces, rather than accelerates, prodrug activation, so acrolein generation would tend to fall.
Option B: Option B is incorrect because azoles inhibit rather than induce CYP3A4; active metabolite formation decreases.
Option D: Option D is incorrect because cyclophosphamide requires enzymatic CYP activation, not spontaneous hydrolysis, so a real interaction exists.
Option E: Option E is incorrect because the dominant effect is reduced hepatic activation, not impaired renal clearance of metabolites.

11. [CASE 3 — QUESTION 3] Continuing with the same patient, a subsequent admission for a mycobacterial infection adds rifampin to her regimen while she is again receiving cyclophosphamide. Integrating rifampin's enzyme effect with cyclophosphamide activation and clearance, which description best captures the interaction?

A) Rifampin induces CYP enzymes, accelerating prodrug activation (raising active metabolite and potential toxicity) while also speeding prodrug clearance (potentially lowering exposure and efficacy)
B) Rifampin inhibits CYP enzymes, uniformly reducing both toxicity and efficacy of cyclophosphamide
C) Rifampin has no interaction with cyclophosphamide, which is activated by spontaneous hydrolysis
D) Rifampin blocks renal excretion of active metabolites, increasing toxicity without affecting activation
E) Rifampin chelates urinary acrolein, reducing the risk of hemorrhagic cystitis

ANSWER: A

Rationale:

Option A is correct. Rifampin is a potent inducer of CYP enzymes, including CYP2B6 and CYP3A4. Induction accelerates activation of cyclophosphamide to its active alkylating metabolite and acrolein, which can increase toxicity, while the same induction can deplete the parent prodrug more rapidly, reducing overall exposure and potentially compromising efficacy. The net effect reflects these opposing pressures.

Option B: Option B is incorrect because rifampin induces rather than inhibits CYP enzymes.
Option C: Option C is incorrect because cyclophosphamide requires CYP activation, so a real interaction exists; spontaneous hydrolysis describes temozolomide.
Option D: Option D is incorrect because the dominant interaction is enzyme induction altering activation and clearance, not a block of renal excretion.
Option E: Option E is incorrect because urinary acrolein binding is the role of mesna, not rifampin.

12. [CASE 3 — QUESTION 4] Continuing with the same patient, her team discusses why normal hematopoietic stem cells tolerate cyclophosphamide relatively well while many tumor cells do not. Which mechanism best explains this selective protection?

A) Normal cells lack the cytochrome P450 enzymes needed to activate cyclophosphamide, so they never form the alkylating metabolite
B) High aldehyde dehydrogenase activity in normal hematopoietic stem cells and hepatocytes inactivates aldophosphamide to non-toxic carboxyphosphamide, sparing those cells
C) Normal cells export phosphoramide mustard through copper-transporting ATPases that tumor cells lack
D) Normal cells repair interstrand cross-links using MGMT, which tumor cells do not express
E) Normal cells convert acrolein to a cytoprotective thiol that neutralizes the alkylating species

ANSWER: B

Rationale:

Option B is correct. Aldehyde dehydrogenase (ALDH) oxidizes aldophosphamide to the non-toxic carboxyphosphamide, diverting it away from forming phosphoramide mustard. Normal hematopoietic stem cells and hepatocytes express high ALDH and are therefore relatively protected, whereas tumor cells with low ALDH activity are comparatively more vulnerable to the active metabolite.

Option A: Option A is incorrect because cyclophosphamide is activated in the liver and active metabolites distribute systemically; normal cells are protected by ALDH-mediated detoxification, not by absence of activation.
Option C: Option C is incorrect because copper-transporting ATPases mediate platinum efflux, not cyclophosphamide metabolite handling.
Option D: Option D is incorrect because MGMT reverses O6-guanine alkylation from methylating agents, not cyclophosphamide cross-links.
Option E: Option E is incorrect because acrolein is a urotoxic byproduct, not a cytoprotective thiol; the protective mechanism is ALDH detoxification of aldophosphamide.

13. [CASE 4 — QUESTION 1] A 36-year-old man receiving ifosfamide for a soft tissue sarcoma becomes increasingly confused and somnolent about 30 hours into the infusion, with new cerebellar ataxia and visual hallucinations. His metabolic panel and head imaging are unremarkable. What is the most appropriate management?

A) Continue the ifosfamide infusion and add lorazepam for presumed delirium
B) Administer hypertonic saline for suspected infusion-related hyponatremia
C) Begin high-dose corticosteroids for presumed leptomeningeal disease
D) Stop the ifosfamide and administer intravenous methylene blue
E) Increase the mesna dose to neutralize the neurotoxic metabolite in the central nervous system

ANSWER: D

Rationale:

Option D is correct. The presentation is ifosfamide encephalopathy, caused by the neurotoxic metabolite chloroacetaldehyde, typically appearing 12 to 48 hours after infusion onset. The appropriate response is to discontinue ifosfamide and administer intravenous methylene blue, which acts as an electron acceptor that reverses the metabolic disturbance underlying the encephalopathy.

Option A: Option A is incorrect because continuing the offending drug allows the encephalopathy to progress; the cause is metabolite-mediated, not primary delirium.
Option B: Option B is incorrect because the metabolic panel is unremarkable, making hyponatremia unlikely; the syndrome is chloroacetaldehyde toxicity.
Option C: Option C is incorrect because imaging is unremarkable and the temporal link to ifosfamide points to encephalopathy, not leptomeningeal disease.
Option E: Option E is incorrect because mesna acts in the urinary tract against acrolein and does not treat chloroacetaldehyde-mediated encephalopathy; the treatment is methylene blue.

14. [CASE 4 — QUESTION 2] Continuing with the same patient, after recovery he resumes a modified sarcoma regimen, and a trainee asks why mesna is mandatory with ifosfamide at every dose but is generally reserved for high-dose cyclophosphamide. What is the best explanation?

A) Ifosfamide generates a greater acrolein load per gram of drug, so urothelial protection with mesna is required at all ifosfamide doses
B) Mesna is required for ifosfamide because it crosses the blood-brain barrier and prevents the encephalopathy, unlike with cyclophosphamide
C) Ifosfamide delivers phosphoramide mustard to the bladder lumen, which mesna neutralizes only at high cyclophosphamide doses
D) Cyclophosphamide generates no acrolein, so mesna is never strictly necessary for it
E) Mesna is mandatory for ifosfamide because it is renally cleared while cyclophosphamide is hepatically cleared

ANSWER: A

Rationale:

Option A is correct. Both drugs generate acrolein, which is excreted in urine and injures the urothelium, but ifosfamide produces a higher acrolein load per gram of drug. Because the urotoxic burden is greater at any ifosfamide dose, mesna is mandatory whenever ifosfamide is used, whereas forced hydration alone often suffices for standard-dose cyclophosphamide and mesna is reserved for high-dose regimens.

Option B: Option B is incorrect because mesna acts in the urinary tract against acrolein; it does not prevent the chloroacetaldehyde-mediated encephalopathy, which is treated with methylene blue.
Option C: Option C is incorrect because the urotoxin reaching the bladder is acrolein, not phosphoramide mustard, and mesna binds acrolein.
Option D: Option D is incorrect because cyclophosphamide does generate acrolein; mesna is simply not always required at standard doses because the load is lower.
Option E: Option E is incorrect because both drugs are eliminated with renal involvement, and the deciding factor is the per-gram acrolein load, not a clearance-route difference.

15. [CASE 4 — QUESTION 3] Continuing with the same patient, after additional ifosfamide cycles he develops hypophosphatemia, a normal-anion-gap metabolic acidosis, glucosuria with normal blood glucose, and aminoaciduria. Which renal toxicity does this pattern represent?

A) Distal renal tubular acidosis from cisplatin, with potassium wasting and nephrolithiasis
B) Proximal tubular dysfunction (Fanconi syndrome) from ifosfamide, with phosphate, bicarbonate, glucose, and amino acid wasting
C) Acute interstitial nephritis from mesna hypersensitivity, with eosinophiluria
D) Glomerular injury from carboplatin, with heavy proteinuria and edema
E) Obstructive uropathy from acrolein crystal deposition in the renal pelvis

ANSWER: B

Rationale:

Option B is correct. Ifosfamide is associated with proximal renal tubular dysfunction (Fanconi syndrome), in which impaired proximal reabsorption produces phosphate wasting (hypophosphatemia), bicarbonate wasting (normal-anion-gap acidosis), glucosuria with normal blood glucose, and aminoaciduria. This toxicity is more prominent with ifosfamide than cyclophosphamide and can be dose-limiting, particularly in pediatric patients.

Option A: Option A is incorrect because the pattern is proximal (Fanconi) dysfunction, not distal renal tubular acidosis, and is attributable to ifosfamide.
Option C: Option C is incorrect because the findings reflect proximal tubular wasting, not allergic interstitial nephritis from mesna.
Option D: Option D is incorrect because the picture is tubular, not glomerular; heavy proteinuria with edema is not the described syndrome.
Option E: Option E is incorrect because acrolein causes urothelial injury (hemorrhagic cystitis), not crystalline obstructive uropathy producing this tubular pattern.

16. [CASE 4 — QUESTION 4] Continuing with the same patient, before a later ifosfamide cycle he is noted to have hypoalbuminemia, a rising serum creatinine, and a documented history of prior cisplatin exposure. Integrating these features with ifosfamide metabolism, what do they collectively predict?

A) A reduced risk of any ifosfamide toxicity, because renal impairment slows formation of the active metabolite
B) An isolated increased risk of hemorrhagic cystitis, unrelated to the listed factors
C) An increased risk of ifosfamide encephalopathy, for which hypoalbuminemia, renal impairment, and prior cisplatin are recognized risk factors
D) A reduced acrolein load, because hypoalbuminemia increases free-drug clearance
E) An increased risk of pulmonary fibrosis, because prior cisplatin sensitizes the lung

ANSWER: C

Rationale:

Option C is correct. Ifosfamide encephalopathy, driven by chloroacetaldehyde, is more likely in the presence of recognized risk factors that include hypoalbuminemia, renal impairment with elevated creatinine, and prior cisplatin exposure. The combination should heighten vigilance for recurrent confusion, somnolence, and ataxia during and after the infusion.

Option A: Option A is incorrect because these factors increase, rather than decrease, the risk of encephalopathy.
Option B: Option B is incorrect because the listed factors specifically predict encephalopathy risk; hemorrhagic cystitis risk relates chiefly to acrolein load and mesna use.
Option D: Option D is incorrect because hypoalbuminemia is a risk factor for encephalopathy, not a mechanism that lowers acrolein burden.
Option E: Option E is incorrect because pulmonary fibrosis is a cumulative carmustine toxicity, not an ifosfamide risk predicted by these factors.

17. [CASE 5 — QUESTION 1] A 68-year-old woman with epithelial ovarian cancer is to receive carboplatin-based chemotherapy. The pharmacist explains that carboplatin is dosed differently from most cytotoxic drugs. Which statement correctly describes the basis of carboplatin dosing?

A) It is dosed in milligrams per kilogram of actual body weight, like most weight-based cytotoxic agents
B) It is dosed empirically by tumor type, with fixed milligram doses assigned to each indication
C) It is dosed by body surface area in milligrams per square meter, identical to the cisplatin approach
D) It is dosed by serum creatinine alone, without reference to any target drug-exposure value
E) It is dosed to a target area under the curve using the Calvert formula, which incorporates renal function

ANSWER: E

Rationale:

Option E is correct. Carboplatin is eliminated almost entirely by renal filtration as the intact complex, so glomerular filtration rate (GFR) is the primary determinant of exposure. The Calvert formula (dose = target AUC multiplied by [GFR plus 25]) sets the dose to achieve a target area under the concentration-time curve, individualizing for renal function, because the dose-limiting thrombocytopenia tracks with exposure.

Option A: Option A is incorrect because carboplatin is dosed to target AUC, not by milligrams per kilogram of body weight.
Option B: Option B is incorrect because dosing is exposure-based via the Calvert formula, not fixed empiric milligrams per indication.
Option C: Option C is incorrect because body-surface-area dosing is the cisplatin approach; carboplatin uses AUC-targeted dosing.
Option D: Option D is incorrect because the Calvert formula uses GFR within a target-AUC calculation rather than serum creatinine alone with no exposure target.

18. [CASE 5 — QUESTION 2] Continuing with the same patient, who is frail with low muscle mass, her carboplatin dose was calculated using an estimated GFR (glomerular filtration rate) derived from serum creatinine. Ten days later she develops grade 4 thrombocytopenia far exceeding expectations. What best explains this outcome?

A) Her tumor developed acute platinum resistance, paradoxically increasing marrow toxicity
B) She received too little carboplatin, and the thrombocytopenia reflects disease progression rather than drug effect
C) Her low muscle mass produced a low creatinine that overestimated GFR, so the Calvert formula assigned an excessive dose and exposure
D) Carboplatin accumulated in the central nervous system, secondarily suppressing the marrow
E) The thrombocytopenia is unrelated to carboplatin, since its dose-limiting toxicity is nephrotoxicity

ANSWER: C

Rationale:

Option C is correct. In a patient with low muscle mass, serum creatinine underrepresents true renal function, so the estimated GFR is falsely high. Because the Calvert formula sets the dose as target AUC multiplied by (GFR plus 25), an overestimated GFR yields an excessive dose and greater-than-intended exposure, producing the severe thrombocytopenia that is carboplatin's exposure-related dose-limiting toxicity.

Option A: Option A is incorrect because resistance reduces antitumor effect and does not increase marrow toxicity.
Option B: Option B is incorrect because the overestimated GFR caused overdosing, not underdosing, and severe thrombocytopenia here is a drug effect.
Option D: Option D is incorrect because carboplatin does not accumulate in the central nervous system to suppress the marrow; the toxicity is a direct exposure effect.
Option E: Option E is incorrect because carboplatin's dose-limiting toxicity is myelosuppression, predominantly thrombocytopenia, directly related to exposure.

19. [CASE 5 — QUESTION 3] Continuing with the same patient, her disease later progresses during carboplatin-based therapy, and a clinician proposes simply switching to cisplatin to overcome resistance. Which statement about platinum cross-resistance is correct?

A) Cisplatin and carboplatin show no cross-resistance, so cisplatin substitution reliably restores response
B) Cisplatin and carboplatin share essentially complete cross-resistance, so substitution generally does not restore response
C) Carboplatin resistance predicts enhanced cisplatin sensitivity because the two form chemically distinct adducts
D) Oxaliplatin is completely cross-resistant with carboplatin and should never be considered after carboplatin failure
E) Cross-resistance among all three platinum agents is complete, making any platinum substitution futile in every tumor type

ANSWER: B

Rationale:

Option B is correct. Cisplatin and carboplatin form identical platinum-DNA adducts and share essentially complete cross-resistance, so substituting cisplatin after carboplatin progression generally does not restore response. Oxaliplatin, by contrast, has bulky DACH adducts that confer only partial cross-resistance, but the cisplatin-carboplatin pairing is fully cross-resistant.

Option A: Option A is incorrect because the two agents are cross-resistant; substitution does not reliably restore response.
Option C: Option C is incorrect because cisplatin and carboplatin form the same adducts and are cross-resistant, not reciprocally sensitizing.
Option D: Option D is incorrect because oxaliplatin cross-resistance is partial, not complete; this option overstates it.
Option E: Option E is incorrect because complete cross-resistance applies to cisplatin and carboplatin specifically, while oxaliplatin is only partially cross-resistant.

20. [CASE 5 — QUESTION 4] Continuing with the same patient, the team reviews how carboplatin's toxicity profile differs from cisplatin's when counseling her about expected adverse effects. Which statement correctly contrasts the two agents' dose-limiting toxicities?

A) Carboplatin's dose-limiting toxicity is myelosuppression (predominantly thrombocytopenia), whereas cisplatin's characteristic dose-limiting toxicity is nephrotoxicity
B) Carboplatin's dose-limiting toxicity is nephrotoxicity, whereas cisplatin's is thrombocytopenia
C) Both agents share peripheral neuropathy as the dose-limiting toxicity, differing only in severity
D) Carboplatin's dose-limiting toxicity is ototoxicity, whereas cisplatin's is hepatic sinusoidal obstruction syndrome
E) Neither agent has a clinically meaningful dose-limiting toxicity at standard doses

ANSWER: A

Rationale:

Option A is correct. Carboplatin's slow-hydrolyzing ligand yields a less reactive species with far less renal, neural, and otologic toxicity than cisplatin, and its dose-limiting toxicity is exposure-related myelosuppression, predominantly thrombocytopenia. Cisplatin's characteristic dose-limiting toxicity is cumulative nephrotoxicity, which is why it requires aggressive hydration and magnesium repletion.

Option B: Option B is incorrect because the assignments are reversed: carboplatin is dose-limited by thrombocytopenia and cisplatin by nephrotoxicity.
Option C: Option C is incorrect because peripheral neuropathy is the dose-limiting toxicity of oxaliplatin, not the shared dose-limiting toxicity of carboplatin and cisplatin.
Option D: Option D is incorrect because ototoxicity is a cisplatin toxicity and sinusoidal obstruction syndrome is a busulfan complication; neither is the carboplatin dose-limiting toxicity.
Option E: Option E is incorrect because both agents have well-defined dose-limiting toxicities at standard doses.

21. [CASE 6 — QUESTION 1] A 57-year-old man with recurrent anaplastic glioma is started on lomustine. A student asks why a nitrosourea is chosen for a primary brain tumor when many alkylating agents penetrate the central nervous system poorly. What property accounts for lomustine's usefulness here?

A) It is actively transported across the blood-brain barrier by a carrier upregulated in glial tumors
B) It is administered intrathecally because systemic formulations cannot reach brain tissue
C) It disrupts blood-brain barrier tight junctions, transiently increasing permeability to itself
D) Its high lipophilicity allows passive diffusion across the blood-brain barrier into the central nervous system
E) It is converted to its active form only within neural tissue by brain-specific cytochrome P450 enzymes

ANSWER: D

Rationale:

Option D is correct. Nitrosoureas such as lomustine and carmustine are highly lipophilic, with a log P substantially above that of most other alkylating agents, allowing passive diffusion across the blood-brain barrier and therapeutically relevant central nervous system concentrations for glioma and primary CNS (central nervous system) lymphoma.

Option A: Option A is incorrect because CNS entry is by passive lipophilic diffusion, not an active tumor-upregulated transporter.
Option B: Option B is incorrect because lomustine is given orally and reaches the CNS; intrathecal administration is not how it is used.
Option C: Option C is incorrect because nitrosoureas do not act by disrupting tight junctions; their CNS access reflects their own lipophilicity.
Option E: Option E is incorrect because nitrosoureas decompose spontaneously in aqueous solution to their reactive species rather than requiring brain-specific CYP activation.

22. [CASE 6 — QUESTION 2] Continuing with the same patient, a covering clinician unfamiliar with nitrosoureas schedules the next lomustine dose at 4 weeks, as is common for many other regimens, and it is administered. He returns at week 5 with profound pancytopenia. What is the best explanation and corrective action?

A) Nitrosoureas have a delayed nadir at 4 to 6 weeks; the week-4 dose preceded recovery from the first, causing cumulative myelosuppression, so the interval should be extended to at least 6 weeks
B) The pancytopenia reflects marrow infiltration by tumor; continue lomustine on the 4-week schedule
C) This is an idiosyncratic immune reaction to lomustine; rechallenge on the same schedule is safe once counts recover
D) The marrow suppression is acrolein toxicity; add mesna and maintain the 4-week interval
E) This is expected nitrosourea behavior with no scheduling implication; resume full-dose dosing immediately

ANSWER: A

Rationale:

Option A is correct. Nitrosoureas produce a characteristically delayed myelosuppressive nadir at 4 to 6 weeks with recovery requiring 6 to 8 weeks, which is why cycles are spaced no more often than every 6 weeks. A dose at week 4 was given before recovery from the first, producing overlapping cumulative myelosuppression; the correction is to extend the interval to at least 6 weeks.

Option B: Option B is incorrect because the timing and scheduling error point to cumulative drug toxicity, and continuing the 4-week schedule would repeat the harm.
Option C: Option C is incorrect because this is predictable delayed myelosuppression from overlapping dosing, not an idiosyncratic immune reaction, and same-schedule rechallenge is unsafe.
Option D: Option D is incorrect because acrolein causes hemorrhagic cystitis, not the delayed marrow suppression of nitrosoureas, and the 4-week interval is the core error.
Option E: Option E is incorrect because, although delayed nadir is expected nitrosourea behavior, it has a critical scheduling implication: the interval must be lengthened, not ignored.

23. [CASE 6 — QUESTION 3] Continuing with the same patient, over subsequent years his glioma is managed with carmustine-based therapy across many cycles, and his cumulative carmustine dose now exceeds 1,200 mg/m^2. He develops progressive exertional dyspnea and a nonproductive cough. Pulmonary function testing shows a restrictive pattern with reduced diffusing capacity, and imaging shows bibasilar fibrosis without infection. What is the correct interpretation and action?

A) This is an infectious pneumonitis; treat with antibiotics and continue carmustine on schedule
B) This is reversible bronchospasm; add an inhaled bronchodilator and proceed with the next carmustine dose
C) This is cardiogenic pulmonary edema from cumulative cardiomyopathy; begin diuresis and resume carmustine
D) This is an allergic reaction to carmustine; premedicate and rechallenge at a reduced dose
E) This is cumulative carmustine pulmonary fibrosis; discontinue carmustine, as established fibrosis is an absolute contraindication to further treatment

ANSWER: E

Rationale:

Option E is correct. Carmustine causes cumulative, dose-related pulmonary fibrosis, characteristically after high total doses (above roughly 1,200 mg/m^2). The restrictive physiology with reduced diffusing capacity and bibasilar fibrosis identifies carmustine pulmonary fibrosis, which once established is an absolute contraindication to further carmustine; the drug must be discontinued.

Option A: Option A is incorrect because imaging shows fibrosis without infection, so antibiotics are not indicated, and continuing carmustine would worsen the injury.
Option B: Option B is incorrect because the restrictive, low-diffusing-capacity pattern with fibrosis is not reversible bronchospasm, and proceeding with carmustine is contraindicated.
Option C: Option C is incorrect because the picture is pulmonary fibrosis, not cardiogenic edema from cardiomyopathy, and resuming carmustine is unsafe.
Option D: Option D is incorrect because cumulative fibrosis is a dose-related toxicity, not an allergic reaction, and rechallenge is contraindicated once fibrosis is established.

24. [CASE 6 — QUESTION 4] Continuing with the same patient, his care team reviews the underlying chemistry to explain his treatment course. When carmustine decomposes spontaneously in aqueous solution, which pair of reactive species is generated, and how do they damage the cell?

A) An aziridinium ion that alkylates DNA and a sulfhydryl that scavenges free radicals
B) A chloroethyl carbonium ion that alkylates DNA and an isocyanate that carbamylates proteins
C) A methyl diazonium ion that methylates O6-guanine and a nitrite that nitrosylates proteins
D) An aquated platinum species that binds N7-guanine and a chloride that suppresses aquation
E) A phosphoramide mustard that cross-links DNA and an acrolein that injures the urothelium

ANSWER: B

Rationale:

Option B is correct. Nitrosoureas decompose non-enzymatically to a chloroethyl carbonium ion, the DNA (deoxyribonucleic acid) alkylating species that ultimately forms interstrand cross-links, and an isocyanate, which carbamylates lysine residues on proteins (including DNA repair enzymes), inhibiting their function and contributing to cytotoxicity.

Option A: Option A is incorrect because the aziridinium ion is the reactive intermediate of nitrogen mustards, not nitrosoureas, and nitrosoureas do not generate a radical-scavenging sulfhydryl.
Option C: Option C is incorrect because the methyl diazonium ion is the temozolomide and dacarbazine methylating species, not the nitrosourea decomposition product.
Option D: Option D is incorrect because aquated platinum species describe cisplatin chemistry, not nitrosoureas.
Option E: Option E is incorrect because phosphoramide mustard and acrolein are cyclophosphamide products, not nitrosourea decomposition species.

25. [CASE 7 — QUESTION 1] A 29-year-old man with Hodgkin lymphoma is receiving a procarbazine-containing regimen and is also taking a selective serotonin reuptake inhibitor (SSRI) for depression. After a dinner of aged cheeses and red wine, he presents with severe headache, hypertension, agitation, diaphoresis, and tremor. What is the most likely explanation?

A) An acute disulfiram-like reaction to the red wine alone, unrelated to his other medications
B) Procarbazine's weak monoamine oxidase inhibition precipitated a hypertensive and serotonergic crisis from tyramine-rich food combined with the SSRI
C) Tumor lysis syndrome from the chemotherapy, producing the autonomic findings
D) Acrolein-mediated systemic toxicity from procarbazine, requiring mesna
E) Ifosfamide-type encephalopathy, requiring methylene blue

ANSWER: B

Rationale:

Option B is correct. Procarbazine is a weak monoamine oxidase inhibitor (MAOI). Tyramine-rich foods such as aged cheeses and red wine can precipitate a hypertensive crisis, and a concurrent serotonergic agent such as an SSRI adds the risk of serotonin syndrome. The headache, hypertension, agitation, diaphoresis, and tremor reflect that combined MAOI-related crisis, managed by stopping the offending exposures and providing supportive blood pressure and serotonergic control.

Option A: Option A is incorrect because, although procarbazine can cause a disulfiram-like reaction with alcohol, the hypertensive-serotonergic picture here reflects MAO inhibition with tyramine and the SSRI, not alcohol alone.
Option C: Option C is incorrect because tumor lysis syndrome causes metabolic derangements and renal injury, not this tyramine-and-SSRI autonomic crisis.
Option D: Option D is incorrect because procarbazine is not associated with acrolein-mediated toxicity, and mesna is not the treatment.
Option E: Option E is incorrect because the presentation is an MAOI-related crisis, not ifosfamide encephalopathy, so methylene blue is not indicated.

26. [CASE 7 — QUESTION 2] Continuing with the same patient, after recovery he is counseled about alcohol use during procarbazine therapy. He later drinks a beer and develops facial flushing, throbbing headache, nausea, and hypotension. What is the mechanism of this reaction?

A) Serotonin syndrome from an interaction between alcohol and the SSRI alone
B) Hypertensive crisis from tyramine in the beer acting through monoamine oxidase inhibition
C) Acute alcohol-induced pancreatitis unrelated to procarbazine
D) A disulfiram-like reaction from procarbazine inhibition of aldehyde dehydrogenase, causing acetaldehyde accumulation
E) Hemorrhagic cystitis triggered by alcohol-enhanced acrolein excretion

ANSWER: D

Rationale:

Option D is correct. Procarbazine inhibits aldehyde dehydrogenase, so alcohol consumption leads to accumulation of acetaldehyde, producing a disulfiram-like reaction with flushing, headache, nausea, and hypotension. Patients should be counseled to avoid alcohol during procarbazine therapy.

Option A: Option A is incorrect because the flushing-headache-nausea-hypotension pattern is a disulfiram-like reaction from acetaldehyde accumulation, not serotonin syndrome.
Option B: Option B is incorrect because this reaction is mediated by aldehyde dehydrogenase inhibition and acetaldehyde, and it presents with hypotension rather than the hypertensive crisis of a tyramine reaction.
Option C: Option C is incorrect because the syndrome is the characteristic disulfiram-like reaction, not pancreatitis.
Option E: Option E is incorrect because procarbazine is not associated with acrolein-mediated hemorrhagic cystitis, and that is unrelated to this alcohol reaction.

27. [CASE 7 — QUESTION 3] Continuing with the same patient, his lymphoma progresses and he proceeds to allogeneic hematopoietic stem cell transplantation with high-dose busulfan conditioning. On day +17 he develops tender hepatomegaly, a 4-kg weight gain with ascites, rising bilirubin, and worsening thrombocytopenia. What is the diagnosis and appropriate directed therapy?

A) Acute graft-versus-host disease of the liver; begin calcineurin inhibitor monotherapy
B) Cisplatin-type nephrotoxicity with fluid overload; restrict fluids and replete magnesium
C) Hepatic sinusoidal obstruction syndrome from busulfan conditioning; administer defibrotide
D) Ifosfamide encephalopathy with hepatic involvement; administer methylene blue
E) Carmustine pulmonary fibrosis presenting with right heart failure; begin corticosteroids

ANSWER: C

Rationale:

Option C is correct. The constellation of tender hepatomegaly, fluid retention with weight gain and ascites, hyperbilirubinemia, and thrombocytopenia following high-dose busulfan is hepatic sinusoidal obstruction syndrome (SOS, formerly veno-occlusive disease). Defibrotide is the approved therapy for established severe SOS, and therapeutic drug monitoring of busulfan AUC reduces the risk by limiting over-exposure.

Option A: Option A is incorrect because the picture of tender hepatomegaly with weight gain and falling platelets after busulfan is SOS, not hepatic graft-versus-host disease treated with a calcineurin inhibitor alone.
Option B: Option B is incorrect because the findings are hepatic congestion, not renal-tubular cisplatin toxicity, and fluid restriction with magnesium does not treat SOS.
Option D: Option D is incorrect because the picture is hepatic SOS, not ifosfamide encephalopathy, and methylene blue is not the treatment.
Option E: Option E is incorrect because the presentation is hepatic SOS, not carmustine pulmonary fibrosis, and corticosteroids are not the directed therapy.

28. [CASE 7 — QUESTION 4] Continuing with the same patient, during busulfan conditioning he is also receiving an azole antifungal that inhibits CYP3A4 (cytochrome P450 3A4). Integrating busulfan metabolism with its principal serious toxicity, what is the central concern and how is it mitigated?

A) CYP3A4 inhibition can raise busulfan exposure, increasing the risk of sinusoidal obstruction syndrome, mitigated by therapeutic drug monitoring of busulfan AUC
B) The azole induces busulfan metabolism, lowering exposure and risking graft failure, mitigated by empirically increasing the dose
C) The interaction increases acrolein production, raising hemorrhagic cystitis risk, mitigated by mesna
D) The azole accelerates renal busulfan clearance, lowering efficacy, mitigated by adding hydration
E) There is no metabolic concern, because busulfan is eliminated unchanged by the kidney independent of CYP

ANSWER: A

Rationale:

Option A is correct. Busulfan is metabolized in part by hepatic CYP3A4 (and by glutathione conjugation), so a CYP3A4 inhibitor can raise busulfan exposure. Because the most serious non-hematologic toxicity of high-dose busulfan is hepatic sinusoidal obstruction syndrome (SOS), and SOS risk rises with over-exposure, therapeutic drug monitoring of busulfan AUC is used to keep exposure within target and reduce that risk.

Option B: Option B is incorrect because the azole inhibits rather than induces CYP3A4, so exposure rises, and an empiric dose increase would worsen the risk.
Option C: Option C is incorrect because acrolein and hemorrhagic cystitis belong to cyclophosphamide and ifosfamide, not busulfan.
Option D: Option D is incorrect because the interaction involves hepatic CYP3A4 metabolism, not accelerated renal clearance.
Option E: Option E is incorrect because busulfan undergoes hepatic metabolism (CYP3A4 and glutathione conjugation) and is not eliminated unchanged by the kidney independent of CYP.